10:52 AM EDT, 08/20/2026 (MT Newswires) -- Biopharmaceutical company Nykode Therapeutics (NYKD.OL) said Thursday it secured a new US patent related to its fully individualized neoantigen-based cancer vaccine candidate, VB10.NEO. The patent from the US Patent and Trademark Office also covers similar modular neoantigen-based cancer vaccines that use alternative targeting units and/or dimerization units. It remains valid for 20 years, through Jan. 5, 2037.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.